

## Evaluation of Capsular Polysaccharide Production by *Haemophilus Influenzae* type B in Different Culture Media

Bianca Dempsey Pinto, Danielle Kuchinski, Lucas Dias Vieira and Mickie Takagi\*

Butantan Institute, Development and Innovation Division - Instituto Butantan, Brazil

### ARTICLE INFO

Received Date: April 15, 2022

Accepted Date: May 17, 2022

Published Date: May 18, 2022

### KEYWORDS

*Haemophilus influenzae* b

Complex medium MMP

Defined medium

Polysaccharide

Cell growth

**Copyright:** © 2022 Takagi M et al., SL Vaccines And Vaccination Journal. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Citation for this article:** Bianca Dempsey Pinto, Danielle Kuchinski, Lucas Dias Vieira and Mickie Takagi. Evaluation of Capsular Polysaccharide Production by *Haemophilus influenzae* type b in different Culture Media. SL Vaccines And Vaccination Journal. 2022; 3(1):118

### Corresponding author:

Mickie Takagi,

Butantan Institute, Process Development Laboratory. Development and Innovation Division - Instituto Butantan, São Paulo, Brazil,

Email: mickie.takagi@butantan.gov.br

### ABSTRACT

*Haemophilus influenzae* b (Hib), an encapsulated Gram-negative coccobacillus, is one of the most common agents of meningitis worldwide. The Hib vaccine is included in the routine immunization schedule of several countries. The capsular polysaccharide, Poliribosyl-Ribitol-Phosphate (PRP), conjugated to a carrier protein is the antigen of the vaccine against Hib. Currently in industrial processes, Hib is cultivated in a soy-peptone and yeast-extract based complex medium (MMP). This work aimed to evaluate whether a chemically defined medium could replace the MMP medium in the PRP production. The use of a defined media could offer several advantages in the whole process and would be of great interest to the industrial PRP production in vaccination programs. The PRP production ranged from 100 to 290 mg L<sup>-1</sup> in the studied semi-defined and defined media. The formulation of several chemically defined media based on literature led to a promising composition as is the case of medium G which presented a production of 295 mg PRP L<sup>-1</sup> with a lower biomass value of 4.8 UA (O.D.<sub>540 nm</sub>) when compared to MMP medium with 395 mg PRP L<sup>-1</sup> and 6.45 UA respectively.

### INTRODUCTION

*Haemophilus influenzae* type b (Hib) is a Gram-negative, rod-shaped, pleomorphic, and facultative anaerobic bacterium that inhabits the human respiratory tract. Of the six known *H. influenzae* (Hi) serotypes (a–f) [1], type b is known to be the most virulent strain, causing pneumonia, bacteremia, and meningitis, generating neurological sequelae in affected surviving children, elderly and immunosuppressed [2,3]. The capsular polysaccharide, Poliribosyl-Ribitol-Phosphate (PRP), is the main virulence factor from Hib strain and it is also a powerful antigen for Hib vaccine [4]. The second-generation Hib vaccine, which induces a T-cell dependent immune response, was produced as a PRP-protein conjugate and licensed in the United States in 1987 [5,6]. Before the introduction of a Hib vaccine in Brazil, held in 1999, the Hib spread was the most common cause of meningitis in children less than two years old and had a large impact on child mortality [7]. Nowadays, the Hib vaccine is included in the routine immunization schedule of more than 100 countries [3]. International health agencies, such as the World Health Organization (WHO), have been encouraging vaccination against Hib in developing countries through polyvalent vaccines, such as the combination with triple diptheria, tetanus and pertussis (DTP) vaccine, hepatitis B vaccine (HepB), and polio vaccine through the Hib Initiative Program, along with the Global Alliance for Vaccine Innovation (GAVI) [8,9].

*H. influenzae* is considered a fastidious microorganism and it has a deficiency in its enzymatic system, requiring micronutrients and some specific components for its growth, also known as factors V and X [10]. Factor V is nicotinamide adenine dinucleotide coenzyme (NAD), which is essential for oxidation-reduction processes in cell metabolism and it is necessary due to the absence of NAD biosynthetic pathways [11,12]. Factor X is hemin, a protoporphyrin IX containing a ferric ion, required for the synthesis of cytochrome c and other iron-containing respiratory enzymes [12].

As a result of its specific micronutrients requirement, complex culture media have been widely used in the literature to promote Hib growth. The culture medium described in the literature for industrial-scale production of the capsular polysaccharide of *H. influenzae* type b (MMP) consists of soy peptone, a vegetal origin compound, as the main nitrogen source and yeast extract supplemented with glucose, hemin, NAD, and inorganic salts [13,14]. Other media containing compounds of animal origin have been reported, such as casein hydrolysate [15,16]. Even though MMP medium provides high PRP production, complex media containing animal origin components are unsuitable for vaccine production due to the risk of contamination with viruses, mycoplasma, and prions [17]. The use of chemically defined media offers several advantages when compared to complex media, such as process reproducibility improvement once all of the chemical components would be known and have a constant concentration, which would allow a consistent performance, avoiding batch-to-batch variation. A defined medium can reduce the cost of large-scale processes, besides enabling studies of the metabolic pathways, nutritional needs for growth, and synthesis of the product of interest. Furthermore, it also offers an advantage for scaling up the purification process and in the analysis of the final products [18].

Studies on Hib cultivation processes using a chemically defined media are rather scarce in the literature. Different compositions of defined media are reported for *H. influenzae* to study of genetics and developmental competence of the microorganism [19-23]. In this context, the objective of this work is to establish the composition of a chemically defined medium for cellular growth and production of *Haemophilus influenzae* type b capsular polysaccharide.

**Table 1: Evaluation of different media for the development of *H influenzae* type b and synthesis of capsular polysaccharide.**

| Component  | Medium |       |        |        |        |        |       |        |
|--|--------|-------|--------|--------|--------|--------|-------|--------|
|  | A      | B     | C      | D      | E      | F      | G     | H      |
| NaCl   | 5      | 5     | 5      | 5      | 5      | 5      | 5     | 5.8    |
| K <sub>2</sub> HPO <sub>4</sub>                    | 2.5    | 2.5   | 2.5    | 2.5    | 2.5    | 3.5    | 3.5   | 3.5    |
| Na <sub>2</sub> HPO <sub>4</sub>                   | 13.1   | 13.1  | 13.1   | 13.1   | 13.1   | -      | -     | -      |
| NaH <sub>2</sub> PO <sub>4</sub> *H <sub>2</sub> O | 3.3    | 3.3   | 3.3    | 3.3    | 3.3    | -      | -     | -      |
| Glucose  | 5      | 5     | 5      | 5      | 5      | -      | -     | -      |
| Yeast Extract                                      | 5      | 5     | -      | -      | -      | -      | -     | -      |
| Bacto Soytone                                      | 10     | -     | -      | -      | -      | -      | -     | -      |
| NAD  | 0.015  | 0.015 | 0.015  | 0.015  | 0.015  | 0.004  | 0.007 | 0.004  |
| Haemin   | 0.03   | 0.03  | 0.03   | 0.03   | 0.03   | 0.03   | 0.015 | 0.03   |
| L-Cystine  | -      | 0.04  | 0.05   | 0.05   | 0.05   | 0.05   | 0.3   | 0.2    |
| L-Aspartic acid                                    | -      | 0.55  | 0.82   | 0.82   | 0.82   | 0.82   | 0.81  | 0.5    |
| L-Glutamic acid                                    | -      | 0.89  | 1.39   | 1.39   | 1.39   | 1.39   | 0.51  | 1.3    |
| L-Arginine   | -      | 0.28  | 0.41   | 0.41   | 0.41   | 0.41   | 0.2   | 0.3    |
| Glycine  | -      | 0.21  | 0.36   | 0.36   | 0.36   | 0.36   | 0.35  | 0.03   |
| L-Lysine   | -      | 0.29  | 0.52   | 0.52   | 0.52   | 0.052  | 0.45  | 0.05   |
| L-Methionine                                       | -      | 0.05  | 0.09   | 0.09   | 0.09   | 0.09   | 0.2   | 0.1    |
| L-Serine   | -      | 0.14  | 0.23   | 0.23   | 0.23   | 0.23   | 0.3   | 0.1    |
| L-Histidine  | -      | 0.11  | 0.17   | 0.17   | 0.17   | 0.17   | 0.2   | 0.01   |
| L-Leucine  | -      | 0.43  | 0.67   | 0.67   | 0.67   | 0.67   | 0.5   | 0.3    |
| L-Tyrosine   | -      | 0.13  | 0.17   | 0.17   | 0.17   | 0.17   | 0.065 | 0.2    |
| L-Glutamine  | -      | 0.01  | 0.03   | 0.03   | 0.03   | 0.03   | 0.75  | 0.3    |
| L-Isoleucine                                       | -      | 0.28  | 0.47   | 0.47   | 0.47   | 0.47   | 0.4   | 0.05   |
| L-Tryptophan                                       | -      | 0.02  | 0.05   | 0.05   | 0.05   | 0.05   | 0.07  | 0.005  |
| L-Valine   | -      | 0.27  | 0.48   | 0.48   | 0.48   | 0.48   | 0.3   | 0.02   |
| L-Threonine  | -      | 0.11  | 0.19   | 0.19   | 0.19   | -      | -     | -      |
| L-Phenylalanine                                    | -      | 0.31  | 0.49   | 0.49   | 0.49   | 0.49   | 0.625 | 0.015  |
| L-Proline  | -      | 0.2   | 0.3    | 0.3    | 0.3    | -      | -     | -      |
| L-Cysteine   | -      | -     | -      | -      | -      | 0.12   | 0.15  | 0.12   |
| Uracil   | -      | -     | 0.1    | 0.1    | 0.1    | 0.1    | 0.2   | 0.1    |
| Hypoxanthine                                       | -      | -     | 0.02   | 0.02   | 0.02   | 0.02   | 0.015 | 0.02   |
| Inosine  | -      | -     | 2      | 4      | 2      | 2      | 1.125 | 2      |
| Thiamine   | -      | -     | 0.004  | 0.008  | 0.004  | 0.004  | 0.01  | 0.0045 |
| Pantothenic acid                                   | -      | -     | 0.0037 | 0.0074 | 0.0037 | 0.0037 | 0.003 | 0.004  |
| NH <sub>4</sub> Cl                                 | -      | -     | 0.022  | 0.022  | -      | 0.22   | 0.22  | 0.22   |
| MgSO <sub>4</sub> *7H <sub>2</sub> O               | -      | -     | 0.5    | 0.5    | 0.5    | 0.43   | 0.43  | 0.43   |
| CaCl <sub>2</sub> *2H <sub>2</sub> O               | -      | -     | 0.029  | 0.029  | 0.029  | -      | -     | -      |
| EDTA   | -      | -     | 0.004  | 0.004  | 0.004  | 0.004  | 0.004 | 0.004  |
| Tween 80   | -      | -     | 0.02   | 0.02   | 0.02   | 0.02   | 0.02  | 0.02   |
| Sodium lactate                                     | -      | -     | 1.6    | 1.6    | 1.6    | 1.6    | 1.6   | 1.6    |
| Glycerol   | -      | -     | -      | -      | -      | 5      | 5     | 5      |
| PVA  | -      | -     | -      | -      | -      | 0.02   | 0.02  | 0.02   |
| CaCl <sub>2</sub>                                  | -      | -     | -      | -      | -      | 0.029  | 0.165 | 0.029  |
| K <sub>2</sub> SO <sub>4</sub>                     | -      | -     | -      | -      | -      | 1      | 1     | 1      |
| KH <sub>2</sub> PO <sub>4</sub>                    | -      | -     | -      | -      | -      | 2.7    | 2.7   | 2.7    |

Components and concentrations were set according to related media in literature and components complex medium. NAD (Nicotinamide adenine dinucleotide), PVA (Polyvinyl alcohol).

## MATERIALS AND METHODS

### Strain

*Haemophilus influenzae* type b strain GB3291 was acquired from the Núcleo de Coleção de Micro-organismos of the Instituto Adolph Lutz, São Paulo. The working seed was prepared according to Takagi et al, 2006 and stored in liquid nitrogen.

### Media composition

Complex medium, semi-defined and defined media were used in this study according to Table 1: A) complex medium MMP [13] as control; B) Bacto Soytone (BD) was replaced for its related constituent amino acids; C) both Bacto Soytone (BD) and Yeast Extract (BD) were replaced by its respective constituent amino acids and, vitamins and inosine were added according to concentrations described by Herriot et al.; D) modified medium C with vitamin concentrations and inosine doubled; E) modified medium E without  $\text{NH}_4\text{Cl}$ .

After a literature review [19,22,23], 36 components were selected and their concentrations were set using 2 criteria: F) only the concentrations of amino acids were equal to medium C; G and H) all component concentrations were set according to literature [22].

### Shake Flasks Experiments

Pre-inoculum was prepared by transferring 400  $\mu\text{L}$  of bacterial suspension ( $1.9 \times 10^9$  CFU  $\text{mL}^{-1}$ ) into a 300 ml Erlenmeyer flask containing 50 ml of culture medium and incubated under static anaerobic condition at 37°C for 6 hours. A volume of the bacterial culture resulting in an optical density of 0.05 AU at 540 nm ( $\text{OD}_{540 \text{ nm}}$ ) was transferred to a 500 mL Erlenmeyer flask containing 100 mL of medium was incubated on a rotative shaker (250 RPM) at 37 °C for 12 hours. A volume of bacterial culture corresponding to the initial OD of 0.1 AU was used as inoculum and the experiments were performed for 12 hours on a rotatory shaker (300 RPM) at 37°C in a 500 mL Erlenmeyer flask containing 100 mL of sterile culture medium.

## Analysis

**Cell growth:** To monitor cell growth, samples were collected each one hour during the cultivation to measure the optical density at 540 nm. Samples were diluted with 0.85% NaCl when  $\text{OD}_{540 \text{ nm}}$  exceeded 0.5 AU, ensuring uniform distribution of the cells insuspension following Lambert-Beer's law.

**Capsular polysaccharide determination:** PRP concentration was measured by high anion exchange chromatography with pulsed amperometric detection (HPAEC-PAD) [24]. The samples were diluted in deionized water to 540  $\mu\text{L}$  and 180  $\mu\text{L}$  of NaOH 400  $\text{mmol L}^{-1}$ . The mixture was incubated at 37 °C for 20 h under alkaline hydrolysis of polysaccharide and neutralized with 180  $\mu\text{L}$  of 400  $\text{mmol L}^{-1}$  acetic acid. A 100  $\mu\text{L}$  of glucose-6-phosphate at 100  $\mu\text{mol L}^{-1}$  was used as an internal standard. A volume of 10  $\mu\text{L}$  of this mixture was injected into the anion exchange column CarboPac PA-10 coupled to pre-column AminoTrap, mounted on the ICS5000 chromatographic system (Thermo Fisher Scientific Inc.). The methodology included the gradients of NaOH and sodium acetate described in by Haan et al., in addition to the electrochemical potentials defined by the authors for the gold electrode. The calibration curve was plotted using a purified PRP standard at 30  $\text{mg L}^{-1}$  in the range of 1 to 12  $\text{mg L}^{-1}$ .

## RESULTS AND DISCUSSION


*H. influenzae* type b is a fastidious bacteria and due to its metabolic needs, the culture medium described in the literature for industrial-scale production of capsular polysaccharide consists of soy peptone and yeast extract, besides glucose, hemin, NAD, and inorganic salts (MMP medium). Figure 1 shows the Hib growth (a) and PRP production (b) in a time course of 12hours considering ten independent shake flask experiments. As expected, experiments presented a high variation of both studied parameters and low reproducibility.

Experiments were performed to evaluate whether components of complex media could be replaced by simple components such as amino acids and vitamins. The elaboration of the defined medium was carried out in two ways:

1) replacing only Bacto Soytone (B) and both Bacto Soytone and Yeast extract at the same time (C - E) for its related constituent amino acids and supplemented with vitamins, salts lactate as reported by Herriot [22]. Considering that medium D

has the double concentration of inosine, thiamin, and pantothenic acid than C, and medium E had the same composition as medium C, but without  $\text{NH}_4\text{Cl}$ ; 2) media F-H were formulated based on the media reported previously for several strains of *Haemophilus influenzae* [19,22,23] and amino acid concentrations in MMP medium [13]. For this purpose, 36 components and their concentrations were selected from the literature. Amino acids concentrations of medium F were equal to medium C. Figure 2 shows the results of cultivation with media A - H. The media in which Bacto Soytone was replaced (B) did not result in cell growth; this indicates that its components play an essential role in cell development. In the media where both Bacto Soytone and Yeast Extract were replaced by the respective amino acids (C,D, and E) and supplemented with salts and vitamins as reported in literature [22], the measured  $\text{OD}_{540\text{nm}}$  ranged from 4.0 to 2.0. Although the supplementation with ammonium chloride seems to increase nitrogen uptake [22], its absence in medium E does not compromise the growth. On the other hand, doubling inosine, thiamin and pantothenic acid slightly decreased cell growth and PRP synthesis. Analyzing polysaccharide production (Figure 2b), the medium MMP (A) showed the highest PRP production of  $350 \text{ mg L}^{-1}$ , and defined medium G reach a production of  $290 \text{ mg L}^{-1}$ . Media C, D, E reached a PRP production close to  $150 \text{ mg L}^{-1}$ . In these media, inosine played a fundamental role since in its absence affects the growth, reflecting also in the polysaccharide production as in medium B. According to literature [25], inosine is the only nucleoside added to the medium (except for NAD), which acts as a growth co-factor. After being degraded into hypoxanthine, it favors the incorporation of thymine and thymidine by *Haemophilus influenzae* [25]. The obtained data indicate that the same could happen with the uracil nucleotide present in the tested medium, resulting in less growth in the absence of inosine. Therefore, the decrease in the growth rate in the absence of this component signals that *Haemophilus influenzae* does not have the genetic machinery for making nucleotides without the presence of at least one ribonucleotide. Inosine has also been described as an essential component for the development of *Haemophilus influenzae* competence [21,25]. In general, defined media F-H had a better performance than defined and semi-defined media B-E based on complex medium A (Figure 2). A major

difference between these media compositions is the main carbon source which is glucose for media A-E and glycerol and sodium lactate in media F-H. These results could indicate that glycerol is a better carbon source than glucose in defined media. It has been shown that glucose uptake in *H. influenzae* depends on an ATP-dependent kinase, in which glucose is phosphorylated and fed into the central metabolism [26]. Then, glucose is fully oxidized into pyruvate through the glycolytic pathway [26]. Acetate is the main product during aerobic growth and formate is the major product during anaerobic growth [27]. Moreover, acetate was found as the major by-product accumulated in the broth during batch fermentations of *Haemophilus influenzae* type b, decreasing the medium pH and inhibiting cellular growth [13].



The glycerol uptake in *H. influenzae* depends on the expression of the *glp F* gene that facilitates the diffusion of glycerol through the membrane and the expression of a glycerol-3-phosphate transporter [26]. Glycerol is converted into dihydroxyacetone phosphate (DHAP) and it is fed into the glycolytic pathway [26]. Studies have shown that L-lactate had a stimulatory effect on the development of competence [28] and cellular growth [29] of Hi strains, which indicates that lactates could be a carbon-source. Beyond that, not much more is known about lactate metabolism in *H. influenzae* [30]. Media F-H have been supplemented with L-cysteine which appears to be an essential sulfur source for *H. influenzae* strains [31]. Arginine, glutamate, pantothenate, thiamin, uracil, and inorganic phosphate have also been determined as minimal substrate requirements for bacterial growth in Rd strains [31].

In a recent study, Farshad and Pour have studied the PRP production in different complex media by Hib. The authors' results have indicated that PRP production is greatly dependent on not only the kind of growth medium but also on various medium components [32]. The differences between Hib growth and PRP production obtained by media F-H (Figure 2c,d) support the possibility of achieving a PRP production similar to the obtained by using complex medium through altering the concentration of essential medium components, as shown in Table 2. Medium G indicates a promising result once it was possible to achieve a PRP production close to the one obtained in complex medium but with a smaller cellular growth, which could facilitate the purification process.




Figure 2: *Haemophilus influenzae* type b (Hib) growth and PRP production in shake flasks cultivations carried out with semi-defined and defined media. a and c) Hib growth is given by Optical Density (O.D.) at 540 nm; b and d) Poliribosyl-ribitol-phosphate (PRP) production in mg L<sup>-1</sup>. Graphs a and c are related to media: A, B, C, D, and E, and graphs b and d are related to media A, F, G, and H.

Table 2: Comparison of OD<sub>540nm</sub> and PRP synthesis among complex medium MMP (A) and three promising different compositions of defined media.

| Medium | O.D. <sub>540nm</sub> | PRP (mg L <sup>-1</sup> ) |
|--------|-----------------------|---------------------------|
| A      | 6.45                  | 350                       |
| F      | 2.1                   | 200                       |
| G      | 4.8                   | 290                       |
| H      | 3.2                   | 145                       |

### CONCLUSION

Complex medium MMP is used traditionally in the production of capsular polysaccharide PRP for vaccine production. However,

working with complex compound result in high deviation in the cell growth and PRP synthesis among different lots. In summary, this work sought to evaluate whether a chemically defined media in *Haemophilus influenzae* type b cultivations could replace complex media MMP, aiming to produce Poliribosyl-Ribitol-Phosphate (PRP), the antigen for Hib vaccine. It is known that chemically defined media can offer several advantages in industrial processes, mainly for vaccine production. By replacing yeast extract and soy-peptone for its related amino acids, we have observed a decrease in Hib growth and PRP production. 36 components were selected from defined media reported in the literature, it was possible to achieve promising results as the medium G which resulted in 295 mg PRP L<sup>-1</sup>, very close to the production of complex medium of 395 mg PRP L<sup>-1</sup>. Moreover, by altering the concentration of these 36 components in these media, differences in cellular growth and PRP production were observed. Additional studies to investigate the effect of each of these selected components seeking to establish an optimal composition are in progress. As a complex system such as bacteria metabolism, studying and optimizing components of a defined medium will require statistical tools to evaluate the obtained results.

### ACKNOWLEDGMENT

This work was supported by BNDES (The Brazilian Development Bank) Grant number 11.2.0322.1/2012 and Butantan Foundation. We are thankful to Mrs. Ana Maria Rodrigues Soares and Mr. Lourivaldo Ignacio de Souza for technical assistance.

### REFERENCES

- Pittman M. (1931). Variation and type specificity in the bacterial species *Haemophilus influenzae*. Journal of Experimental Medicine. 53: 471-471.
- Watt JP, Wolfson L, O'Brien KL, Henkle E. (2009). Burden of disease caused by *Haemophilus influenzae* type b in children younger than 5 years: global estimates. The Lancet. 374: 903 -911.
- WHO. (2001). Estimating the local burden of *Haemophilus influenzae* type b (Hib) disease preventable by vaccination : a rapid assessment tool.
- Crisel RM, Baker RS, Dorman DE. (1975). Capsular polymer of *Haemophilus influenzae*, type b. I. Structural



- characterization of the capsular polymer of strain Eagan. *Journal of Biological Chemistry*. 250: 4926 -4930.
5. Granoff DM, Cates KL. (1985). *Haemophilus influenzae* type b polysaccharide vaccines. *The Journal of Pediatrics*. 107: 330 -336.
  6. Weinberg GA, Granoff DM. (1988). Polysaccharide-protein conjugate vaccines for the prevention of *Haemophilus influenzae* type b disease. *The Journal of paediatrics*. 113: 621-631.
  7. Peltola H. (2000). Worldwide *Haemophilus influenzae* type b disease at the beginning of the 21st century: Global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. *Clinical Microbiology Reviews*. 13: 302 - 317.
  8. WHO. (2013). *Haemophilus influenzae* type b (Hib) Vaccination. *Weekly Epidemiological Record*. 39: 413-428.
  9. Le P, Nghiem VT, Swint JM. (2013). Post-GAVI sustainability of the *Haemophilus influenzae* type b vaccine program: The potential role of economic evaluation. *Human Vaccines and Immunotherapeutics*. 12: 2403-2405.
  10. Evans NM, Smith DD, Wicken AJ. (1974). Haemin and nicotinamide adenine dinucleotide requirements of *Haemophilus influenzae* and *Haemophilus parainfluenzae*. *Journal of Medical Microbiology*. 7: 359-365.
  11. Niven DF, O'Reilly T. (1990). Significance of V-factor dependency in the taxonomy of *Haemophilus* species and related organisms. *International Journal of Systematic Bacteriology*. 40: 1-4.
  12. Greenwood D, Barer MR, Slack RCB, Irving WL. (2012). *Medical Microbiology: Eighteenth Edition*. *Medical Microbiology: Eighteenth Edition* (Elsevier Inc.).
  13. Takagi M, Cabrera-Crespo J, Zangirolami TC, Raw I, Tanizaki MM. (2006). Improved cultivation conditions for polysaccharide production by *H. influenzae* type b. *Journal of Chemical Technology and Biotechnology*. 81: 182-188.
  14. Maitre-Wilmotte, Ghislaine, Denis Speck, B. R. (2009). Culture medium for *Haemophilus influenzae* type B. 16.
  15. Merritt J, Allard G, O'Toole L, Swartz R, Licari P. (2000). Development and scale-up of a fed-batch process for the production of capsular polysaccharide from *Haemophilus influenzae*. *Journal of Biotechnology*. 81: 189 -197.
  16. Wilwert MW, Parizoto JC, da Silva MR, Albani SMF. (2011). The use of soybean peptone in bacterial cultivations for vaccine production. in *Soybeans: Cultivation, Uses, and Nutrition* (ed. Maxwell, J. E.) 387 - 400 (Nova Science Publishers, Inc).
  17. Jayme DW, Smith SR. (2000). Media formulation options and manufacturing process controls to safeguard against introduction of animal origin contaminants in animal cell culture. *Cytotechnology*. 33: 27-36.
  18. Baltz RH, Demain AL, Davies JE, Bull TA, Junker B, et al. (2010). *Manual of Industrial Microbiology and Biotechnology*. *Manual of Industrial Microbiology and Biotechnology, Third Edition* (American Society of Microbiology).
  19. Butler LO. (1962). A Defined Medium for *Haemophilus influenzae* and *Haemophilusparainfluenzae*. *Journal of General Microbiology*. 27: 51-60.
  20. Coleman HN, Daines DA, Jarisch J, Smith AL. (2003). Chemically defined media for growth of *Haemophilus influenzae* strains. *Journal of Clinical Microbiology*. 41: 4408-4410.
  21. Spencer HT, Herriott RM. (1965). Development of competence of *Haemophilus influenzae*. *Journal of Bacteriology*. 90: 911-920.
  22. Herriott RM, Meyer EY, Vogt M, Modan M. (1970). Defined Medium for Growth of *Haemophilus influenzae*. 101: 513-516.
  23. Talmadge MB, Herriott RM. (1960). A chemically defined medium for growth, transformation, and isolation of nutritional mutants of *Hemophilus influenzae*. *Biochemical and Biophysical Research Communications*. 2: 203-206.
  24. de Haan A, van der Put RMF, Beurret M. (2013). HPAEC-PAD method for the analysis of alkaline hydrolyzates of *Haemophilus influenzae* type b capsular polysaccharide. *Biomedical Chromatography*. 27: 1137-1142.
  25. Carmody JM, Herriott RM. (1970). Thymine and thymidine uptake by *Haemophilus influenzae* and the labeling of deoxyribonucleic acid. *Journal of Bacteriology*. 101: 525 - 530.

26. Gunnewijk M, Sulter G, Postma P, Poolman B. (1997). Regulation of Carbon Metabolism in Bacteria. in Molecular Mechanisms of Signalling and Membrane Transport. 319-330.
27. Othman DSMP, Schirra H, McEwan AG, Kappler U. (2014). Metabolic versatility in *Haemophilus influenzae*: a metabolomic and genomic analysis. *Frontiers in Microbiology*. 5: 69.
28. Miller DH, Huang PC. (1972). Identification of competence-repressing factors during log-phase growth of *Haemophilus influenzae*. *Journal of Bacteriology*. 109: 560-564.
29. Holländer R. (1976). Energy metabolism of some representatives of the *Haemophilus* group. *Antonie van Leeuwenhoek*. 42: 429-444.
30. Lichtenegger S, Bina I, Roier S, Bauernfeind S, Keidel K, et al. (2014). Characterization of lactate utilization and its implication on the physiology of *Haemophilus influenzae*. *International Journal of Medical Microbiology*. 304: 490-498.
31. Schilling CH, Palsson B. (2000). Assessment of the metabolic capabilities of *Haemophilus influenzae* Rd through a genome-scale pathway analysis. *Journal of Theoretical Biology*. 203: 249-283.
32. Farshad N, Pour NA. (2014). Effect of culture media and their ingredients on PRP production by *Haemophilus influenzae*. *International Journal of Current Microbiology and Applied Sciences*. 3: 920-925.